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Abstract
Chondrosarcomas are malignant tumors of the cartilage that are chemoresistant and radioresistant to X-rays. This restricts
the treatment options essential to surgery. In this study, we investigated the sensitivity of chondrosarcoma to X-rays and
C-ions in vitro. The sensitivity of 4 chondrosarcoma cell lines (SW1353, CH2879, OUMS27, and L835) was determined by
clonogenic survival assays and cell cycle progression. In addition, biomarkers of DNA damage responses were analyzed in
the SW1353 cell line. Chondrosarcoma cells showed a heterogeneous sensitivity toward irradiation. Chondrosarcoma cell
lines were more sensitive to C-ions exposure compared to X-rays. Using D10 values, the relative biological effectiveness of
C-ions was higher (relative biological effectiveness ¼ 5.5) with cells resistant to X-rays (CH2879) and lower (relative
biological effectiveness ¼ 3.7) with sensitive cells (L835). C-ions induced more G2 phase blockage and micronuclei in
SW1353 cells as compared to X-rays with the same doses. Persistent unrepaired DNA damage was also higher following
C-ions irradiation. These results indicate that chondrosarcoma cell lines displayed a heterogeneous response to conven-
tional radiation treatment; however, treatment with C-ions irradiation was more efficient in killing chondrosarcoma cells,
compared to X-rays.
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Introduction
Chondrosarcomas are defined as malignant tumors of the
cartilage accounting for about 10% of all bone tumors with
different malignant potential depending on histological grad-
ing.1,2 Since chondrosarcomas are considered to be resistant
to conventional chemo- and radiotherapy,3 the first line of
treatment is complete surgical resection of the tumor. Nev-
ertheless, patients with inoperable lesions (eg, due to
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location) are treated with high-dose radiotherapy (68-74
Gy).4-8 However, it is still unclear why the efficacy of con-
ventional radiotherapy is still weak for high-grade chondro-
sarcoma. Radiotherapy technologies were constantly
improved over several decades, with the emergence of
intensity-modulated radiotherapy or stereotactic radiother-
apy,9,10 leading to better control of localization and an
increased dose to the tumor, while sparing the healthy tissue
of risk organs, with promising results, particularly in the
treatment of nasopharyngeal carcinoma.11 Nevertheless, con-
ventional radiotherapy (X-rays/photon) is not the preferred
standard therapy for inoperable chondrosarcomas. Indeed,
whenever possible, irradiation with accelerated ions is per-
formed. Hadron therapy, using protons and C-ions, allows a
single-dose deposit, specifically within the tumor volume,
preserving surrounding radiosensitive organs thanks to dis-
tribution of the irradiation particles in matter within the
Bragg peak.12-15 At equivalent physical doses, C-ions pres-
ent higher biological efficacy against tumor cells than
photons (X-rays) and protons.16-20 Such efficacy was
observed by comparing clonogenic survival of cancer cells
irradiated with different radiation qualities. The “relative
biological effectiveness” (RBE) can be calculated with the
ratio of the dose of each radiation (ions vs photons) inducing
10% of clonogenic survival (D10). The RBE of C-ions was
estimated between 1.5 and 7 depending on the cells and
culture conditions used and the linear energy transfer (LET)
of the native C-ions beam.16,17,19,21 According to this pro-
mising biological efficacy, several studies used C-ions irra-
diations against different X-ray-resistant cancer cells, in
vitro, in preclinical and clinical studies. Delivery of irradia-
tion with this quality requires the development of special
infrastructures, comprising large ion accelerators (synchro-
tron), thus limiting the access to such treatment to a small
number of patients and reducing the possibilities of large-
scale clinical studies. Nevertheless, several countries are
now able to study the benefits of ion radiotherapy applied
to X-ray-resistant tumors mostly in Japan, Italy, and Ger-
many. Several installations are planned to be developed in
the near future all over the world. A new center dedicated to
research with accelerated light ions will be erected in Caen,
France (ARCHADE, Advanced Resource Center for
HADrontherapy in Europe) and will contribute to the prog-
ress of the scientific knowledge on hadronbiology and
hadrontherapy. The goal of this study was to analyze the
responses of different chondrosarcoma cell lines to C-ions
irradiations and estimate the advantage of this irradiation
procedure compared to X-rays in targeting malignancy. Dif-
ferent C-ion beams were used for this study, including the C-
ions beam from Grand Accele´rateur National d’Ions Lourds
(GANIL, Caen, France) and from Heavy Ion Medical Accel-
erator in Chiba (HIMAC) facility of QST (Chiba, Japan).
The different technical approaches provided data converging
to the same conclusion, namely that C-ions irradiation is
more efficient than X-rays at killing chondrosarcoma cells,
and demonstrate a high RBE for X-ray-resistant cell lines.
Materials and Methods
Cell Culture
The chondrosarcoma cell line SW1353 (CLS Cell Lines Ser-
vice GmbH, Eppelheim, Germany) initiated from a primary
grade II chondrosarcoma of the right humerus from a 72-
year-old female Caucasian was cultured in “chondrocyte
growth medium” as previously described22 using culture
medium from CellSystems (#411PR-500; Troisdorf, Ger-
many). The chondrosarcoma cell line CH287923,24 was initi-
ated from a primary grade III chondrosarcoma of the chest wall
from a 35-year-old female and was cultured in RPMI 1640
(Sigma-Aldrich, Saint-Quentin Fallavier, France), supplemen-
ted with 10% fetal calf serum (Sigma-Aldrich). The chondro-
sarcoma cell line OUMS2725 was initiated from a primary
grade III chondrosarcoma of the humerus from a 65-year-old
male and was cultured in minimum essential medium Eagle
(MEM, M5650; Sigma-Aldrich), supplemented with 5% fetal
calf serum (Sigma-Aldrich). The chondrosarcoma cell line
L83526 was initiated from a primary grade III chondrosarcoma
of the humerus from a 55-year-old male and was cultured in
MEM (M5650; Sigma-Aldrich), supplemented with 10% fetal
calf serum (Sigma-Aldrich). The SW1353 cell line was com-
mercially available; the CH2879, OUMS27, and L835 were
obtained from the Department of Pathology, Leiden University
Medical Center (Leiden, the Netherlands). All cell lines were
cultured in humidified atmosphere with 5% CO2 and cartilage
physioxia condition with 2%O2 at 37
C, in a Heracell 150i Tri-
Gas incubator. All experiments (passages, etc) were performed
outside of the incubator, as fast as possible, to limit the impact
of a higher oxygen tension on cell metabolism. To keep 2% O2
during irradiation, flasks without “cap filter” were used and the
cap was closed during the short period of irradiation. This study
does not report research involving human participants.
Irradiations
X-rays were applied at doses between 1 and 8 Gy. The photon
beam was delivered at room temperature (20C) with a tube
tension of 225 kV, a copper filter, and an intensity of 10 mA
corresponding to a dose rate of 2 Gy/min on the Pxi XradSmart
225cX irradiator, dedicated to preclinical research, with a
lower energy compared to clinical radiotherapy (4-18 MV).
The flasks were irradiated horizontally and the medium was
changed immediately after irradiation. The dose rate was mea-
sured inside flasks with thermoluminescent dosimeters in the
irradiation conditions (same distance to the source, same scat-
tering volume below the flask) at 225 kV and 13 mA with a 0.3
mm filtration of copper. Thermoluminescent dosimeters were
preliminary calibrated on a 15-cm-thick virtual water phantom
thanks to reference dose measurements performed with a cali-
brated ionization chamber following the “American Associa-
tion of Physicists in Medicine protocol,” developed by the
Radiation Therapy Committee Task Group 61, for reference
dosimetry of low- and medium-energy X-rays for radiotherapy
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and radiobiology. Dose rate was finally corrected from the used
tube current.
For C-ions exposure, irradiations were delivered at room
temperature (20C) on 2 different irradiation platforms. Flasks
were irradiated vertically, completely filled with medium. The
medium was changed immediately after irradiation. Due to the
low availability of beam time with such facilities, not all
experiments and conditions were performed with all systems.
Clonogenic assays, cell cycle analysis, and Western blotting
were performed with the GANIL facility, using the IRABAT
beam line.27 Two LETs were compared to a native12 C C-ions
beam of 95 MeV/A using a PMMA (poly-methyl methacrylate)
device inserted between the exit of the beam and the sample
holder. Without PMMA (native beam), the LET was 28 keV/mm
(2 Gy ¼ 4.46  107 particles/cm2); and using a 16.9 mm thick-
ness PMMA (degraded beam), the LET was 73 keV/mm (2 Gy¼
1.71  107 particles/cm2). In the present study, LET is consid-
ered as high when equal or superior to 28 keV/mm.
Micronuclei assays with C-ions were performed at the
HIMAC facility. The cells were exposed to C-ions beam at the
HIMAC of the National Institute of Radiological Sciences
(Chiba, Japan), at room temperature. C-ions were accelerated
with an initial energy of 290 MeV/n and the cells were irradiated
at the center of a 6 cm spread-out Bragg peak region, with an
average LET of 50 keV/mm. In the procedure of dose calibration,
the physical dose ismeasuredwith a traceable ionization chamber
by the standard method authorized by Japan Society of Medical
Physics according to the International Atomic Energy Agency
(IAEA) protocol.28,29 The measurement value is converted to the
absorbed dose to water and evaluated as Gy/the monitor counts.
Clonogenic Assays
This method is used to screen the sensitivity of cells to irradia-
tion or combined treatment. For this approach, cells at 90%
confluency are directly irradiated in 25 cm2 flasks. A sham
control is done to evaluate the plating efficiency; this repre-
sents the 0 Gy control condition. The medium in the irradiated
flasks was changed immediately after irradiation and then the
flasks are returned to the incubator for at least 18 hours. Next,
the cells are harvested and replated with appropriate dilutions
in the multiwell plates. Six-well plates are used with 2 plating
densities, in order to obtain about 100 and 1000 colonies per well
in control samples. Each well contains 2 mL of medium, neces-
sary for the cellular growth and division. After an incubation
period of at least 8 days, the colonies are simultaneously fixed
and stained with a crystal violet solution (0.3% wt/vol crystal
violet in 20% vol/vol ethanol). Only colonies containing more
than 50 cells were counted visually with a stereomicroscope. The
results are expressed as a percentage of control unirradiated
cells. A linear quadratic model of cell survival is used to fit the
results obtained with X-rays according to the equation:
SFðDoseÞ ¼ expða Doseþ b Dose2Þ:
A linear model of cell survival is used to fit the results
obtained with C-ions irradiation according to the equation:
SFðDoseÞ ¼ expða DoseÞ
All curves were fitted with a dedicated tool for Clonogenic
Survival Calculation, the CS-cal software (www.oncoex-
press.de), and the corresponding parameters (SF2 ¼ surviving
fraction at 2 Gy; D10 ¼ irradiation dose giving 10% survival
and D37 ¼ irradiation dose giving 37% survival) were
calculated.
Colony Size Distribution
Colony size distributions (CSDs) were determined by allowing
single cells to form colonies over the course of 11 days, fol-
lowed by crystal violet staining, and the number of cells in each
colony was counted visually with a stereomicroscope. Colony
size distribution data are reported as a cumulative probability
distribution of the percentage of cells able to form colonies of
greater than or equal to n cells after a defined growth inter-
val.30,31 Nonparametric Wilcoxon test was used as the data did
not meet the assumptions of normal distribution (Supplemen-
tary Data 2). The analysis was performed using the computer
software R, version 3.1.2 (2014-10-31).
Cell Cycle Analysis
Following irradiation, the cells were plated at subconfluency in
25 cm2 culture flasks, then placed in the incubator from 6 to 48
hours. The cells were incubated with 100 mM of 5-ethynyl-20-
deoxyuridine (EdU) during 2 hours before harvest. The cells
were then harvested and centrifuged at 135g for 5 minutes. The
cell pellet was washed in phosphate buffered saline (PBS),
fixed in ethanol 75%, then stored at 4C prior analysis. Finally,
the cells were centrifuged at 845g for 5 minutes and the cell
pellet was resuspended in PBS þ BSA (1%) before staining.
Fixed cells were stained with Click-iT EdU assay kits for flow
cytometry from Thermo Fisher Scientific (Waltham, Massa-
chusetts). Briefly, after permeabilization with 0.1% saponin
(15 minutes), the cells were stained with Click-iT reaction mix
for 30 minutes (dark room). The cells and all pellets of washing
steps were suspended in 500 mL DNA Prep Stain (containing
propidium iodide) and 50 mL DNA Prep LPR (DNA Prep
Reagent Kit; Beckman Coulter, Pasadena, California). Samples
were incubated in the dark for 15 minutes and a minimum of 1
 104 cells per sample were analyzed using GALLIOS flow
cytometer (Beckman Coulter). FlowJo analyzing software
(Ashland, Oregon) was used. Experiments were repeated 4
times and data expressed as mean+ standard error of the mean
(SEM). A one-way analysis of variance (ANOVA) statistic test
was applied for each time point (red for low LET and blue for
high LET; *P < .05, **P < .01, and ***P < .001).
Western Blotting Analysis
Following irradiation, cells were detached from the flasks at
different time points, centrifuged at 845g for 5 minutes, and the
cell pellets were mixed with T-PER lysis buffer supplemented
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with a protease and phosphatase inhibitors cocktail (ref 78440;
Thermo Fisher). This cell lysis step was followed by addition of
Laemmli buffer and a denaturation at 100C. The extracted
sample was then separated by SDS-PAGE and transferred to
a nitrocellulose membrane according to Hamdi et al.22 Mem-
branes were analyzed against anti-H2AX phospho-serine 139
(clone JBW301; Merck, Fontenay-sous-Bois, France), anti-
GAPDH (MA5-15738; Fisher, Illkirch, France), and anti-p21
(2947; Cell Signaling, Denver, Colorado). Membranes were then
incubated with HRP-conjugated secondary antibody (mouse or
rabbit; 1:10000; GE Healthcare). The membranes were treated
with electrochemiluminescence reagent (Merck KGaA, Darm-
stadt, Germany) before exposure to hyperfilms (VWR,
Fontenay-sous-Bois, France). The films were developed and
scanned as JPEGs using a GS 700 Bio-Rad scanner (Bio-Rad,
Hercules, CA).
In Vitro Micronucleus Test
The cells were plated on 10-mm-diameter glass coverslips
placed in 24-well plates so that they reach subconfluence at
the time of analysis. About 22 hours before harvest and 4 hours
after irradiation, cytochalasin B (Sigma-Aldrich) was added at
a concentration of 3 mg/mL in culture medium. For the analysis
of micronuclei, the cells were washed with PBS and fixed in
cold acid acetic (10% vol/vol) in methanol solution for 20
minutes. The coverslips were mounted on glass slides with
Prolong Gold Anti-Fade reagent with DAPI (Invitrogen, Paris,
France) which allowed staining of the DNA. For each experi-
mental point, 500 binucleated cells were analyzed per slide, for
at least 3 slides. Themicronuclei were scored only in binucleated
cells where the 2 nuclei had similar size and staining intensity
and did not present nuclear condensation or any other morphol-
ogy abnormalities. The micronuclei were considered when they
were about 1/3 to 1/16 of the size of nucleus and presented
similar staining intensity. The experiments were repeated at least
3 times and data expressed as mean + SEM. A one-way
ANOVA test was applied to assess significance at the .05 level.
Results
Clonogenic Survival Is Reduced With C-Ions as Compared
to X-Ray Radiation
The clonogenic survival was calculated for the 4 chondrosar-
coma cell lines with increasing doses of X-rays or C-ions. Eigh-
teen hours following irradiations at culture confluency, the cells
were seeded in culture flasks at low density and the plating
efficiencies of SW1353, CH2879, OUMS27, and L835 cells
were 0.17 + 0.02, 0.51 + 0.08, 0.32 + 0.05, and 0.34 +
0.04, respectively. The cells were kept in a humidified incubator
at 5%CO2 and 2%O2 for at least 8 days, until large clones could
be observed but without cells merging from different clones.
Cloneswithmore than 50 cells were counted and survival curves
were fitted by Linear-Quadratic (LQ) equation in case of X-rays
and linear model in case of C-ions irradiations (Figure 1).
Figure 1. Comparison of clonogenic survival of 4 chondrosarcoma
cell lines irradiated with different radiation qualities. The surviving
fractions of chondrosarcoma cells irradiated with 225 kV X-rays (blue
squares), 28 keV/mm C-ions (red squares), and 73 keV/mm C-ions
(green squares). Four chondrosarcoma cell lines were plotted with the
same irradiation conditions: (A) (SW1353), (B) (CH2879), (C)
(OUMS27), and (D) (L835). The symbols and the bars corresponded
respectively to the means and standard errors from at least 3 inde-
pendent experiments. The data were fitted with the linear quadratic
equation in case of X-rays irradiations, and with a linear equation for
C-ions irradiations, as explained in the corresponding paragraph of the
“Materials and Methods.” The plots were obtained from the CS-cal
software, which allowed the calculation of survival and biological
effectiveness parameters (Table 1).
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Considering X-rays, the L835 cell line was observed as the
most sensitive with a D10 of 4.16+ 0.11 Gy; and the OUMS27
and SW1353 cell lines were the most resistant with a D10 of
about 6.7 Gy (6.76 + 0.5 and 6.84 + 0.51, respectively); the
CH2879 cell line displayed an intermediate resistance with a
D10 of 5.92+ 0.29 Gy, but not significantly different with the
OUMS27 and SW1353 cell lines (Table 1). The same radio-
resistance was observed when considering the surviving frac-
tion at 2 Gy (SF2). The factors D10, D37, and SF2 illustrated
that the 3 cell lines SW1353, CH2879, and OUMS27 presented
a similar response to X-rays, while the L835 cell line demon-
strated the highest radiosensitivity.
Higher LET irradiations induced a decrease in the surviving
fraction, observed for all cell lines, intermediate with C-ions at
28 keV/mm and higher with C-ions at 73 keV/mm (Figure 1). In
case of irradiation with C-ions at 28 keV/mm LET, the highest
RBE, calculated with the ratio of D10 (X-rays/C-ions), was
obtained with CH2879 and L835 cells, ranging between 2.40
and 2.52, respectively (Table 1). The lowest RBE (2.05) was
observed with OUMS27 cells; the RBE of the cell lines
SW1353 was intermediate (2.32). When considering the RBE
with the ratio of D37, the lowest RBE (2.42) was still observed
with OUMS27 cells and the highest (3.22) with CH2879 cells,
the 2 other cell lines (SW1353 and L835) showed an intermedi-
ate RBE of about 2.8 (Table 1). In case of irradiation with
C-ions at high LET (73 keV/mm), an increased RBE was
observed for all cell lines, but CH2879 cell line displayed the
highest RBE (D10) with a factor of 5.48, when compared to
X-rays. With the cell lines SW1353 and OUMS27, an RBE
higher than 5 was observed (5.11 and 5.18, respectively), and
the lowest RBE was obtained with the L835 cell line (3.72),
possibly related to the higher sensitivity to X-rays of this last
cell line. When considering the SF2 after C-ions irradiation at
73 keV/mm, CH2879 and L835 cell lines were the most sensi-
tive (0.014 + 0.001 and 0.016 + 0.001, respectively), and
SW1353 and OUMS27 cell lines were the most resistant
(0.029 + 0.001 and 0.030 + 0.002, respectively).
Each cell line was characterized for the CSD following
exposure to irradiation in order to assess the intrinsic differ-
ences in growth and division potential of chondrosarcoma cell
lines (Figure 2). Both X-ray and C-ion exposures at a single
dose of 2 Gy reduced significantly the growth and division
potential of chondrosarcoma cell lines. However, the respec-
tive impact of X-rays and C-ions was very different from one
line to another. Indeed, the SW1353 line showed a light but
significant effect of X-rays compared to sham, while C-ions
presented a strong impact (Figure 2A). Both CH2879 and
OUMS27 cell lines (Figure 2B and C) showed a fair intermedi-
ate effect of X-rays on division potential in between sham and
C-ions irradiations. Finally, the L835 cell line (Figure 2D) dis-
played a major impact of both radiation modalities, although a
significant difference remains measurable between photons
and C-ions.
The cell line SW1353 displayed an average RBE and radio-
resistant responses to X-rays and C-ions. The following experi-
ments presented in this study were focused on this cell line,
reducing the number of samples to be analyzed, and in relation
to the reduced access to C-ions beams to perform these
experiments.
C-Ion Irradiation Induced a G2 Blockage and Major DNA
Damages
SW1353 cells were analyzed by flow cytometry to estimate the
percentage of cells in each cycle phase and the capacity of
irradiation to block cells on specific phases. Following 2 Gy
Table 1. Parameters and Calculated RBE for Cell Survival (From Figure 1 and Supplemental Table 1).
D10a D37b SF2c RBE (D10)d RBE (D37)e
SW1353 X-raysf 1.3 keV/mm 6.84 +0.51 3.74 +0.64 0.64 +0.09 / /
Carbong 28 keV/mm 2.94 +0.19 1.27 +0.08 0.21 +0.02 2.32 2.95
Carbong 73 keV/mm 1.34 +0.02 0.58 +0.01 0.03 +0.00 5.11 6.51
CH2879 X-rays 1.3 keV/mm 5.92 +0.29 3.43 +0.16 0.63 +0.05 / /
Carbon 28 keV/mm 2.47 +0.28 1.07 +0.12 0.15 +0.03 2.40 3.22
Carbon 73 keV/mm 1.08 +0.01 0.47 +0.01 0.01 +0.00 5.48 7.37
OUMS27 X-rays 1.3 keV/mm 6.76 +0.50 3.44 +0.18 0.57 +0.03 / /
Carbon 28 keV/mm 3.29 +0.25 1.42 +0.11 0.24 +0.03 2.05 2.42
Carbon 73 keV/mm 1.30 +0.10 0.56 +0.05 0.03 +0.01 5.18 6.15
L835 X-rays 1.3 keV/mm 4.16 +0.11 1.93 +0.16 0.36 +0.03 / /
Carbon 28 keV/mm 1.65 +0.05 0.71 +0.02 0.06 +0.01 2.52 2.70
Carbon 73 keV/mm 1.12 +0.01 0.48 +0.01 0.02 +0.00 3.72 3.99
Abbreviation: RBE, relative biological effectiveness.
aThe D10 dose gives a surviving fraction of 0.1.
bThe D37 dose gives a surviving fraction of 0.37.
cThe SF2 fraction is observed at a 2 Gy irradiation.
dRelative biological effectiveness (D10) values are calculated as (D10 X-rays)/(D10 C-ions).
eRelative biological effectiveness (D37) values are calculated as (D37 X-rays)/(D37 C-ions).
fThe voltage is 225 kV.
gThe initial energy of the C-ions beam is 95 MeV/A.
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X-rays and C-ions at 28 keV/mm, cells were fixed at different
time points and analyzed by flow cytometry (Figure 3).
According to the (sham) unirradiated control, 22.7% (+0.6)
of SW1353 cells were in G2/M phase at 6 hours (Figure 3, open
circle, bottom) and 43.9% (+1.3) of cells were in G1 phase
with a maximum (54.4%+ 4.3) after 15 hours (Figure 3 open
circle, top). When considering X-irradiated cells (Figure 3,
filled circle), a significant increase in the G2/M phase popula-
tion was observed, with a maximum (36.9% + 2.3) 9 hours
after irradiation. The level of this population (Figure 3, filled
circle, bottom) went back to the level of the unirradiated con-
trol 18 hours after irradiation. At the opposite, the level of the
G2/M phase population stayed significantly higher to the sham
irradiated control when cells were irradiated with 2 Gy C-ions.
For C-ion irradiation, the blockage in G2 reached the maximum
after 12 hours (45.9% + 2.7) and then decreased to a plateau
(30.7% + 5.3) but without reaching the level of the control.
Indeed, C-ions induced a longer G2/M phase arrest as
compared to X-rays. No sub-G1 fraction could be observed
following 2 Gy irradiations (X-rays and C-ions).
In addition, a higher amount of micronuclei was observed
following C-ions irradiation, as compared with X-rays
(Figure 4). SW1353 cells irradiated with 2 Gy C-ions at 50
keV/mm displayed about 500 micronuclei per 1000 binucleated
cells (499+ 30), while about 375 micronuclei per 1000 binu-
cleated cells (374 + 20) were induced by 2 Gy X-rays in our
conditions.
C-Ion Irradiation Delayed DNA Damage Repair
Following irradiation (X-rays and C-ions 28 keV/mm),
SW1353 cells were analyzed by Western blotting to estimate
the relative amount of specific proteins markers (g-H2AX and
p21) of irradiation responses (Figure 5). With both irradiation
qualities, g-H2AX level was maximum at 1 hours after irradia-
tion and then decreased until 96 hours following irradiation.
Figure 2. Colony size distribution of 4 chondrosarcoma cell lines irradiated with different radiation qualities. Four chondrosarcoma cell lines
were plotted with the same irradiation conditions: A (SW1353), B (CH2879), C (OUMS27), and D (L835). The symbols corresponded to 3
experiments; blue diamond (control), red square (2 Gy X-rays), and green triangle (2 Gy 28 keV/mm C-ions). Control, X-rays, and C-ions plots
were significantly different, excepted in case of the L835 cell line (X-rays vs C-ions), Supplementary Data 2.
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The maximum level of g-H2AX was higher with X-rays, com-
pared to C-ions, but a tendency to a plateau occurred with
C-ions from 12 hours after irradiation, while a constant
decrease was observed with X-rays (Figure 5A and B, top),
in agreement with a study in human fibroblasts.32
The level of the cell cycle inhibitor p21 increased from 1
hour after irradiation, with a maximum at 24 hours (Figure 5B,
middle). Both irradiation types increased p21 expression in the
DNA damage response, but with a lower level after C-ion
irradiation.
Discussion
Chondrosarcomas are mainly considered as resistant to con-
ventional radiotherapy (X-rays). But in case of a nonresect-
able localized disease and the ineffectiveness of
chemotherapy, radiotherapy is the only available treatment.7
Owing to the close proximity of risk organs (brain, cochlea,
brain stem), a dose increase is difficult with X-rays in case of
commonly observed localization of chondrosarcoma (skull
base). Consequently, the efficiency of radiotherapy against
such X-ray-resistant tumor needs to be improved, and the use
of accelerated ions can be a solution.33 Indeed, such noncon-
ventional radiotherapy (with protons and/or C-ions) has pro-
ven its capacity to improve treatment against X-ray-resistant
cancers.34 The present study indicated that heavy ions may
be a superior method at identical physical doses to induce
chondrosarcoma cell killing in vitro compared to X-rays,
based on using 4 chondrosarcoma cell lines with various
radiosensitivities. Numerous studies have already shown that
high LET irradiation, involving accelerated heavy ions, are
more effective for cell killing than low LET irradia-
tions.17,21,35,36 High LET radiation qualities are considered
to generate a large number of complex clusters of DNA
damage which would be more difficult to repair, resulting
in more severe biological damages than that induced by low
LET radiation.37,38
Moreover, the clonogenic survival data confirmed the trend
previously shown in prostate cancer in an in vivo study, that
there is much larger variation in radiosensitivity with photons
than with high LET radiation.39
In the present study, the RBE values for the 4 chondrosar-
coma cell lines ranged from 2.04 to 7.30 relative to X-rays,
depending on the LET of C-ions beams and the calculation of
the factor, with D10 or D37 ratios. We observed that RBE was
Figure 3. Cell cycle progression of chondrosarcoma cells after
exposure to different radiation qualities at a dose of 2 Gy. The cell
cycle distribution of SW1353 cells unirradiated (empty circle), irra-
diated with X-rays (filled circle), and 28 keV/mm C-ions (filled
square) is compared between G0/G1 (top panel), S (middle panel), and
G2/M phases (bottom panel) at different time points following irra-
diation (from 6 to 48 hours). Time points significantly different from
control were reported with 1 star (P < .05), 2 stars (P < .01), and 3 stars
(P < .001), in red in case of X-rays irradiation and in blue in case of
C-ions.
Figure 4. Micronucleus induction in sw1353 chondrosarcoma cells
irradiated with X-rays and 50 keV/mm C-ions. Results from X-rays
experiments are means of 2 independent experiments. Results from
the C-ions experiment are from 1 irradiation experiment. The data
presented are a mean (with standard errors) of at least 3 technical
repetitions. One-way ANOVA on raw data was performed at the 0.05
level; the mean values were significantly different (*), P ¼ 2.07 E-8.
ANOVA indicates analysis of variance.
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lower using the X-ray-sensitive cell line (L835). With the 3
X-ray-resistant chondrosarcoma cell lines, the RBE was about
2.2 using D10 ratio and an LET of 28 keV/mm LET, and about
5.2 at 73 keV/mm LET. No correlation could be done between
cell response to radiation and p53 status, since only SW1353
cells appeared as p53 mutated (V203L), CH2879, OUMS27,
and L835 were p53 wild type.23,40
Taken together, all these results clearly show that the anal-
ysis of one parameter was not enough to understand the radio-
sensitivity of a cell line. The RBE of C-ions was indeed related
to the increased cell killing effect of high LET irradiation,
while it was related to the relative radiosensitivity of cell of
the X-rays too (Table 1).
These clonogenic survival assays allowed us to classify the
cell lines (from the less resistant to the most resistant) accord-
ing to their radiosensitivity to:
1. X-rays: L835 < CH2879-SW1353-OUMS27 (P < .05)
2. C-ions at 28 keV/mm: L835 < CH2879 < OUMS27-
SW1353 (P < .05)
3. C-ions at 73 keV/mm: CH2879 < L835 < SW1353-
OUMS27 (P <.05)
These RBE values of chondrosarcoma cells were in the
range of the previously published studies on various
tumors.16,17,21
These values were of particular interest in relation to the use
of RBE-corrected dose (Cobalt Gray equivalent) in particle
therapy. But in order to follow the recommendation about har-
monization of radiobiological studies,41 we kept for this whole
article physical dose in Gy.
The present study proposes for the first time a comparison
between C-ions with different LET and X-rays on 4 chondro-
sarcoma cell lines. Since these types of cell lines were irra-
diated for the first time in those conditions, and in vitro, it is
difficult to extrapolate these results to medical treatments.
Nevertheless, the RBE obtained with high LET C-ions on
X-ray-resistant cells were higher than previously reported RBE
on osteosarcoma,21 showing the promising potential of such
irradiation on the control of chondrosarcomas.
In the present study, we confirmed the difficulty of cells to
repair high LET irradiation damages, with different technical
approaches on a single X-ray-resistant chondrosarcoma cell
line. The SW1353 chondrosarcoma cell line was selected for
further and deeper analysis of DNA repair mechanism follow-
ing high LET irradiation. Indeed, C-ions irradiation induced a
prolonged blockage of SW1353 cells in G2 phase and a con-
comitant high level of g-H2AX protein, in agreement with
previous studies in prostate and colon cancer cells.42 Compared
to X-rays, C-ions irradiation induced 30% of additional micro-
nuclei. This result is coherent with another study showing an
increase in the MN frequency as a function of LET after 2 Gy
irradiation with the SW1353 cell line. They observed from 35%
of binucleate cells with micronuclei with C-ions (LET ¼ 13
keV/mm), to 80% of binucleate cells with micronuclei with iron
ions (LET ¼ 151 keV/mm).43
In conclusion, the results of the present study provide a basis
and a radiobiological confirmation into the possibility of
application of heavy ions in medical treatment of chondrosar-
coma.7,33 With the use of several X-ray-resistant chondrosar-
coma cell lines, this study clearly pointed out the significant
effectiveness of high LET C-ions in killing chondrosarcoma
cells, with physical doses comparable with X-rays. X-ray-
resistant cells exhibited higher RBE values for C-ions. These
findings support the capacity of accelerated ions in the treat-
ment of X-ray-resistant tumor. Nevertheless, many radiobiolo-
gical studies are still needed to understand all the mechanisms
involved in the biological activity of heavy ions, including the
role of the isocitrate dehydrogenase enzyme mutation
Figure 5. Western blotting analysis of Sw1353 cells at different time
points following irradiation (X-rays and C-ions 28 keV/mm). SW1353
cells were analyzed by Western blotting to estimate the variation
kinetics of specific proteins markers to irradiation responses. A con-
trol (0 Gy) at 1 hour and irradiated samples (2 Gy) were compared
from 1 to 96 hours following treatment. Different antibodies were
used, g-H2AX, p21, and GAPDH were analyzed by Western blotting
(A) and the corresponding signal was quantified with the Quantity One
software (Bio-Rad, Hercules, California) and normalized against the
signal of the GAPDH loading control (B). Gamma-H2AX and X-rays
partially from Hamdi et al.22.
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status,44,45 the possibility of neighborhood effect, that is,
bystander effect,46,47 and the accessibility to radiosensitizing
chemicals, for example, Parp inhibitors.33,48 All these areas of
study are of great interest for radiobiologists, in order to
improve the treatment of resistant and aggressive tumor and
to preserve surrounding healthy tissues.
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